Drug Database
TA

tamsulosin (tamsulosin WOWTAB / Harnal D)

✓ Approved

Astellas Pharma · ADRA1A · Small Molecule

What is tamsulosin?

tamsulosin is a small molecule developed by Astellas Pharma. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namestamsulosin WOWTAB, Harnal D
CompanyAstellas Pharma
Drug ClassSmall Molecule
Molecular TargetADRA1A
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

tamsulosin acts on 1 molecular target:

ADRA1Aadrenoceptor alpha 1A (ALPHA1AAR, ADRA1C)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

tamsulosin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersBenign prostatic hyperplasia✓ Approved

Related Research Articles

PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Efficacy of human umbilical cord mesenchymal stem cells in the treatment of chronic nonbacterial prostatitis in rats].

DU Haiyan H, Zhang Kun K, Zhang Qin Q, Li Linghui L et al.

Objective To investigate the efficacy of human umbilical cord mesenchymal stem cell (hUCMSC) for the treatment of chronic nonbacterial prostatitis (CNP) model rats. Methods Thirty-two male Sprague-Dawley rats were randomized into four experimental subgroups: control, model, tamsulosin, and hUCMSC, with eight animals allocated to each group. CNP models were induced in all subgroups, except the control. After 28 days of modeling, the hUCMSC group was injected weekly with 1×106 cells/kg P5 hUCMSC cell suspension by tail vein for 4 weeks. In the control and model groups, equivalent volumes of normal saline were administered via injection. And the tamsulosin group was given daily gavage of 0.022 mg/kg tamsulosin solution for 28 days. After 4 weeks of treatment, the basic indexes including body weight, intake and water intake, and prostate index were analyzed in each group, HE staining was performed to characterize the histopathological features of the prostate. The levels of serum TNF-α, IL-1β, and IL-10 in rats were detected by ELISA. qRT-PCR was used to detect the mRNA expression of TNF-α and IL-1β in prostate tissues. And Western blot was performed to detect the protein expression of the NF-κB inflammatory pathway. Results At the end of treatment, compared with the model group, the body weight and water intake of the rats in the tamsulosin group and hUCMSC group increased significantly (P<0.05). There was a significant decline in prostate indexes and prostate wet weight (P<0.01). And interstitial inflammatory cells in prostate tissues were reduced. The levels of serum TNF-α and IL-1β and the expression of TNF-α and IL-1β mRNA in prostate tissues were significantly reduced (P<0.01). An opposite tendency was observed in IL-10 levels (P<0.01). p-IκBα/IκBα and p-NF-κB p65/NF-κB p65 ratios were significantly reduced (P<0.01). Conclusion hUCMSC improve the pathological state of rat prostate, inhibit the overexpression of pro-inflammatory factors, down-regulate the phosphorylation level of NF-κB signaling pathway, and alleviate the inflammatory response in CNP rats.

PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Effects of biofeedback electrical stimulation integrated with Chinese medicine emotional care on alleviating symptoms in the patients with chronic prostatitis/chronic pelvic pain syndrome].

Tang Xue X, Wu Hui H, Ning Gang G, Peng Ajian A et al.

Objective To evaluate the efficacy of biofeedback electrical stimulation combined with Chinese medicine emotional nursing in improving symptoms among patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Methods Seventy patients who met the inclusion criteria of CP/CPPS were randomly divided into the conventional group and the combined intervention group, with 35 cases in each group. The control group received oral tamsulosin sustained-release capsules along with routine care. In addition to the conventional treatment, the patients in combined intervention group received biofeedback electrical stimulation combined with Chinese Medicine emotional nursing. Biofeedback electrical stimulation was administered three times per week for a total of 8 weeks. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), International Prostate Symptom Score (IPSS), Hamilton Anxiety Rating Scale (HAMA), and Hamilton Depression Rating Scale (HAMD) were used to assess patients at baseline, 4 weeks, and 8 weeks of intervention. Results No significant differences in baseline data were observed between the two groups before the intervention (P>0.05). After 4 and 8 weeks of intervention, both groups showed significant improvements in NIH-CPSI, IPSS, HAMA and HAMD scores compared to baseline (P<0.05). Compared to the control group, the combined intervention group demonstrated significantly greater reductions in the total NIH-CPSI score, its pain subscore, IPSS score, and HAMA score at both 4 and 8 weeks (P<0.05). By the 8th week, the combined intervention group also showed a significantly greater reduction in the NIH-CPSI urination subscore and HAMD score (P<0.05). However, no statistically significant intergroup difference was found in the NIH-CPSI quality of life subscore (P>0.05). Furthermore, the combined intervention group achieved significantly higher rates of nursing satisfaction (97.05%) and overall efficacy (91.18%) compared to the control group (P<0.05). Conclusion The combined intervention of biofeedback electrical stimulation and Chinese Medicine emotional nursing can significantly alleviate urinary symptoms, pelvic pain, and anxiety-depression moods in patients with CP/CPPS. Although there was no statistically significant difference in the quality of life scores between the two groups, the combined intervention may provide potential benefits for the long-term improvement of patients' quality of life in terms of the improvement of core clinical symptoms and emotional states.

PubMedCell reports. Physical science2026-11-11

Ultrasound-activated drug release with extracellular vesicles.

Shi Xi X, He Weilong W, Xu Haiyue H, Dasgupta Rinki R et al.

Precise, noninvasive targeting and controlled drug release to the nervous system can transform both basic research and clinical therapy. Ultrasound combined with artificial carriers offers a promising approach for precise, noninvasive drug release. Here, we report a focused ultrasound (FUS)-responsive delivery system based on extracellular vesicles (EVs), which are naturally occurring, biocompatible phospholipid nanocarriers. To enable ultrasound responsiveness, the lipid-gas phase-transition material perfluoropentane (PFP) is co-encapsulated with therapeutic agents into EVs via low-temperature sonication. The resulting EVs are 100-200 nm in size and demonstrate efficient, on-demand release upon ultrasound stimulation. In primary cultured neurons, FUS-triggered release from EVs loaded with PFP and lidocaine suppresses neuronal activity with minimal cytotoxicity. We further demonstrate in vivo modulation of pain sensitivity in rats. Overall, this EV-based platform enables safe, ultrasound-activated drug delivery and supports therapeutic applications of lipid nanocarriers.

PubMedHSS journal : the musculoskeletal journal of Hospital for Special Surgery2026-11-11

The Relationship Between Preoperative Cervical Muscle Morphology and Reciprocal Cervical Alignment Changes After Lumbar Pedicle Subtraction Osteotomy: A Retrospective Cohort Study.

Verna Bruno B, Burkhard Marco D MD, Guven Ali E AE, Mielke Anna-Maria AM et al.

Lumbar sagittal realignment induces compensatory changes throughout the thoracic and cervical spine. Given the role of cervical musculature in head posture, we sought to evaluate whether preoperative cervical muscle morphology is associated with immediate cervical alignment changes following lumbar pedicle subtraction osteotomy (PSO). We conducted a retrospective cohort study in which lumbar PSO patients with preoperative and immediate postoperative (1-30 days) standing whole-spine radiographs were reviewed. C2 to 7 sagittal vertical axis (cSVA) was measured. For muscle analysis, a subset with preoperative cervical MRI was included. At C3, anterior muscle group (AG) and trapezius (TP) functional cross-sectional area (fCSA) and fatty infiltration (FI) were obtained. Ninety-nine patients were included in the initial analysis. Mean cSVA significantly decreased from 30.4 to 26.7 mm. Twenty-two patients had a preoperative cervical MRI available for muscle analysis. Spearman correlation analysis showed that greater TP fCSA correlated with larger postoperative reductions in cSVA, whereas greater TP FI correlated with smaller reductions in cSVA. Larger AG fCSA also correlated with smaller reductions in cSVA. Preoperative cervical muscle morphology was associated with reciprocal cervical alignment changes after PSO. Greater TP fCSA correlated with larger postoperative reductions in cSVA, whereas greater TP FI correlated with smaller reductions. Larger AG fCSA also correlated with smaller immediate cervical alignment changes. Together, these findings suggest that the relative balance between posterior stabilizing and anterior cervical muscle quality may influence the magnitude of acute cervical decompensation following thoracolumbar realignment. Level IV, retrospective cohort study.

PubMedNational science review2026-11-11

Programmable multifunctional microrobots for synergistic cuproptosis-immunotherapy.

Li Chuanhua C, Li Jiaxin J, Liu Xuejia X, Chen Xuyang X et al.

Oral microrobots as drug carriers have shown great promise in enhancing the therapeutic efficacy of colorectal cancer (CRC). However, existing platforms frequently lack the programmable temporal precision required to execute complex, multistage dosing regimens. Here, we report a programmable temporal-responsive microrobot (PTRM) that autonomously navigates across the gastric acid barrier under external magnetic guidance to execute a sequential drug-release program at orthotopic tumor sites. The PTRM is engineered with a logic-gated architecture, featuring a spatially specific shell for gastric-resistant shielding and exclusive intestinal pH-triggered activation. The system's internal 'timer' is governed by the precise modulation of crosslinking densities within its dual gelatin cores, enabling finely-tuned biphasic release kinetics. Phase 1 executes the programmed release of elesclomol to induce tumor cell cuproptosis, successfully priming the tumor microenvironment by recruiting infiltrating immune cells. Following a precisely tuned 5.5 h interval, Phase 2 triggers the release of PD-1 inhibitors to activate these cells, thereby amplifying immunogenic cell death. This orchestrated sequential cytotoxicity achieved a 76% remission rate in an orthotopic CRC mouse model. Furthermore, the PTRM architecture is highly scalable, accommodating up to six-core configurations for multiphase release-establishing a versatile robotic platform for complex combinatorial therapeutic strategies against recalcitrant cancers.

PubMedBiomaterials science2026-11-11

Correction: Tailoring the biological performance of titanium implants via a TaCu nanocoating on MAO-porous layers: the interplay between surface topography and controlled Cu2+ release.

Yao Litao L, Tong Yuanhao Y, Lin Xiaohong X, Huang Mengmeng M et al.

Correction for 'Tailoring the biological performance of titanium implants via a TaCu nanocoating on MAO-porous layers: the interplay between surface topography and controlled Cu2+ release' by Litao Yao et al., Biomater. Sci., 2026, https://doi.org/10.1039/d6bm00600k.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about tamsulosin